Itske Fraterman

PhD student

+31205122480 Lonneke van de Poll

The incidence of melanoma continues to rise. In recent years, the introduction of immunotherapy with immune checkpoint-inhibitors (ICIs) have significantly improved the outcome of melanoma patients and they have become standard of care. Collecting patient-reported outcomes (PROs) and HRQoL data is important for understanding the short-term and long-term impact of melanoma itself and the treatment with ICIs on quality of life outcomes in melanoma patients. During my PhD trajectory, in general, I will focus on PROs in melanoma patients treated with ICIs. This is however, captured in different projects, and introduced below.

My main project will be a Horizon2020 European Union funded project called “Cancer Patients Better Life Experience” (CAPABLE). A second study I will be coordinating is the “Patient Reported Outcomes in high risk and advanced MELanoma patients” (PRO-MEL) study. Lastly, a project I am involved in is the implementation of a standard set of PROMs in clinical practice in the Antoni van Leeuwenhoek (AvL) hospital.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.